ArticleFrontiers in pharmacology2024

Enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma: a cost-effectiveness analysis from China based on the EV-302 trial.

Maojin You et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.